COMP <GO>
TMDX vs LIVN // REVENUE GROWTH (YOY)
TransMedics Group Inc. (NASDAQ) VS. LivaNova PLC (NASDAQ) • 15-METRIC TALLY: TMDX 8
— LIVN 3
▲ REVENUE GROWTH (YOY) LEADER: TMDX
LAST: $65.99 (-1.68%) • MKT CAP: $2.33B
revenue-growth
37.10%
LAST: $78.97 (-2.81%) • MKT CAP: $4.48B
revenue-growth
10.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TMDX VS. LIVN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TMDX | LIVN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.90% | 67.70% | -7.80 | LIVN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.10% | 17.30% | +0.80 | TMDX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.6x | 15.6x | -1.00 | TMDX | /valuation <GO> |
| Free Cash Flow Yield | 5.74% | 3.87% | +1.87 | TMDX | /fcf-yield <GO> |
| Operating Margin | 17.90% | 14.40% | +3.50 | TMDX | /operating-margins <GO> |
| Net Profit Margin | 31.40% | -17.50% | +48.90 | TMDX | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 37.10% | 10.70% | +26.40 | TMDX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.50 | 2.21 | +1.29 | TMDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | TMDX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 32.5 | 58.2 | -25.70 | LIVN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.2x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.33B | $4.48B | -$2.15B | LIVN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TMDX REV | LIVN REV | TMDX GROSS % | LIVN GROSS % | TMDX FCF | LIVN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $605.5M | $1.39B | 59.9% | 67.7% | $133.6M | $173.3M |
| FY 2024 | $441.5M | $1.25B | 59.4% | 68.1% | -$80.9M | $135.9M |
| FY 2023 | $241.6M | $1.15B | — | — | -$13.0M | $74.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TMDX // BETA —
LIVN // BETA —